|  |  |  |  |
| --- | --- | --- | --- |
| Table S5. Clinical characteristics and laboratory indices of severe and critically ill patients with COVID-19 on admission. | | | |
| **Clinical Characteristics** | **Critically ill patients** | | |
| Female (n=21) | Male (n=21) | *P* value |
| Age, Median (IQR), y |  |  | 0.696 † |
| Age, n (%) |  |  | 0.292 § |
| ≤60 | 4 (19%) | 7 (33.3%) |  |
| ＞60 | 17 (81%) | 14 (66.7%) |  |
| Comorbidities, n (%) |  |  |  |
| Hypertension | 10 (47.6%) | 10 (47.6%) | 1.000 § |
| Diabetes | 5 (23.8%) | 4 (19%) | 1.000 ‡ |
| Chronic respiratory diseases | 1 (4.8%) | 4 (19%) | 0.341 ‡ |
| Malignancy | 2 (9.5%) | 1 (4.8%) | 1.000 ‡ |
| Chronic kidney disease | 0 (0%) | 2 (9.5%) | 0.469 ‡ |
| Chronic liver disease | 1 (4.8%) | 3 (14.3%) | 0.599 ‡ |
| Coexisted comorbidities, n (%) | 12 (57.1%) | 15 (71.4%) | 0.334 § |
| Treatment, n (%) |  |  |  |
| Antiviral therapy | 16 (76.2%) | 21 (100%) | 0.057 ‡ |
| Antibacterial | 20 (95.2%) | 19 (90.5%) | 1.000 ‡ |
| Glucocorticoid therapy | 13 (61.9%) | 18 (85.7%) | 0.160 § |
| Immunoabsorption | 3 (14.3%) | 1 (4.8%) | 0.599 ‡ |
| Oxygen inhalation, n (%) |  |  | 0.035 ‡ \* |
| High ﬂow nasal cannula | 4 (19%) | 12 (57.1%) |  |
| Noninvasive ventilation | 11 (52.4%) | 6 (28.6%) |  |
| Invasive mechanical ventilation | 6 (28.6%) | 3 (14.3%) |  |
| Clinical outcomes, n (%) |  |  | 0.013 § \* |
| Survivors | 6 (28.6%) | 14 (66.7%) |  |
| Non-survivors | 15 (71.4%) | 7 (33.3%) |  |
| Abbreviations: IQR, interquartile range; NA, not applicable; COVID-19, 2019 novel coronavirus disease. †: Mann-Whitey U test; §: Chi-squared test; ‡: Fisher's Exact Test. \*: P＜0.05. | | | |